Testing the addition of targeted radiotherapy to surgery & the usual systemic therapy for malignant pleural mesothelioma

Currently Unavailable for Patients


About This Study

NRG-LU006 was a clinical trial studying whether adding targeted radiation therapy called IMPRINT to the usual treatment of surgery and systemic therapy with chemotherapy or immune therapy, can help to extend the life of people with malignant pleural mesothelioma (MPM). MPM is a tumor of the tissue that lines the surface of the lungs. Usual treatment includes a pleurectomy/decortication which is surgery to remove the malignant mesothelioma along with the pleura which is the lung lining followed by chemotherapy drugs. Recently, immune therapy has been approved to treat MPM and can be given before surgery either with chemotherapy or alone. Researchers want to know if IMPRINT, which is a technique that targets radiation treatment directly to the pleura, in addition to surgery and systemic therapy will be as good as or better than the usual treatment of the surgery plus systemic therapy alone (without IMPRINT). 

This study closed to patient enrollment on November 20, 2023.



More information about this particular study is located on ClinicalTrials.gov



About NRG Oncology

At NRG Oncology, we focus on conducting clinical studies aimed to improve current cancer care practices and the lives of cancer patients. NRG Oncology partners with more than 1,300 member sites world-wide to research ways to improve treatment standards in the cancer community. Our organization is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trial's Network.